Ellicott City, MD, United States of America

Lai-Xi Wang

This inventor holds 24 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Glycoengineering Technologies. Top assignee: University System of Maryland. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lai-Xi Wang. Retrieved from https://idiyas.com/inventor/lai-xi-wang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 5)

% Patents Active = 83.3

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 1.7

ph-index = 9

Forward Citations = 193(Granted Patents)

Company Filing History:

25 out of 2,025

University System of Maryland

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Glycosynthases

Chemoenzymatic Synthesis

Antibody Conjugation

Glycoproteins

Transglycosylation

Glycopeptides

Fc Fragments

Fucosylation

HIV Vaccines

Multivalent Inhibitors

Enzymatic Remodeling

Glycoengineering

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12497643 - ENDO-S2 MUTANTS AS GLYCOSYNTHASES, METHOD OF MAKING AND USE FOR GLYCOENGINEERING OF GLYCOPROTEINS (2025-12-16),

2. 12139509 - Fc glycan remodeling platform method for site-specific antibody conjugation and applications thereof (2024-11-12),

3. 11845970 - Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins (2023-12-19),

4. 11643450 - Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof (2023-05-09),

5. 11459380 - Transglycosylation of endo-S and endo-S mutants for antibody glycosylation remodeling (2022-10-04),

6. 11193155 - Designer α 6-fucosidase mutants enable direct core fucosylation of intact N-glycopeptides and N-glycoproteins (2021-12-07),

7. 11008601 - Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins (2021-05-18),

8. 10905702 - Inhibition of galectin 3 binding to the airway epithelial surface to treat or prevent septic shock resulting from influenza and subsequent pneumococcal pneumonia infection (2021-02-02),

9. 10851174 - Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof (2020-12-01),

10. 10836815 - Generation and comparative kinetic analysis of new glycosynthase mutants fromendoglycosidases for antibody glycoengineering (2020-11-17),

11. 10836805 - Chemoenzymatic glycoengineering of antibodies and FC fragments thereof (2020-11-17),

12. 10344063 - Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof (2019-07-09),

13. 9850473 - [object Object] (2017-12-26),

14. 9845360 - Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof (2017-12-19),

15. 9605050 - Glycoprotein synthesis and remodeling by enzymatic transglycosylation (2017-03-28),

Title: The Innovative Mind of Lai-Xi Wang

Introduction: Lai-Xi Wang, a pioneering inventor based in Ellicott City, MD, is known for her groundbreaking contributions to the field of biotechnology.

Latest Patents: Wang's most recent patents focus on novel drug delivery systems that aim to revolutionize the way medications are administered and absorbed in the body.

Career Highlights: With a career spanning over two decades, Wang has established herself as a leading figure in the biotech industry, with numerous awards recognizing her innovative work.

Collaborations: Wang has collaborated with top research institutions and pharmaceutical companies to further develop and commercialize her inventions, solidifying her reputation as a trailblazer in the field.

Conclusion: Lai-Xi Wang's dedication to pushing the boundaries of biotechnology through her inventive spirit and collaborative efforts continues to inspire the next generation of innovators in the industry.

Profile summary based on public USPTO records.